Authors
Latest:
CAR T Therapy as a New Option in Non-Hodgkin Lymphoma: Michael R. Bishop, MDThe hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Latest:
George Tachas, PhD, on Tackling DMD Treatment From Multiple AnglesThe lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.
Latest:
Tim Miller, PhD, on Supporting Gene Therapy DevelopmentThe cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
Latest:
The Future of Gene Therapies in Inherited Retinal DiseasesMariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
Latest:
Advantages of Invariant Natural Killer T Cell TherapiesJennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed the company’s iNKT cell platform.
Latest:
John Leonard, PhD, on RNA-Targeting Gene Therapy for ALS, DMDThe chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.
Latest:
Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy DevelopmentThe head of research at Mass General Brigham’s Cell and Gene Therapy Institute discussed work the center is engaged in with cell and gene therapy.
Latest:
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene TherapyThe codirector of the MDA Clinic and professor of neurology at Johns Hopkins discussed the importance of continuing to fight for progress with older patients with SMA.
Latest:
David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMDThe senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.
Latest:
Electrotransfection: A Different Approach to Plasmid DeliveryThe chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.
Latest:
Daniel Judge, MD, on Translational Gene Therapy for Cardiac DisordersGenetics is the future of heart failure and cardiomyopathy treatment, Judge told CGTLive in an interview.
Latest:
Serena De Vita, MD, PhD, on Speedy Manufacturing of PHE885 for Multiple MyelomaThe senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
Latest:
Paula Cannon, PhD, on What Attendees Can Look Forward to at ASGCT’s 2024 MeetingThe President Elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC also discussed recent milestones in gene therapy.
Latest:
Ula V. Jurkunas, MD: CALEC Transplant Feasible for Limbal Stem Cell DeficiencyThe associate professor of ophthalmology at Harvard Medical School discussed early results from a phase 1/2 trial from Mass Eye and Ear and partners.
Latest:
Raphaël Ognar on Adding New Options to the Oncologic Cell Therapy ArsenalThe cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.
Latest:
Bone Marrow DNA Sequencing Predicts Acute Lymphoblastic Leukemia Relapse After TisagenlecleucelFindings from the phase 2 ENSIGN and ELIANA studies suggest DNA sequencing predicts ALL relapse.
Latest:
Diane Simeone, MD, on Screening Patients for CAR-T Eligibility Before Solid Tumor RelapseSimeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.
Latest:
Francesca Del Bufalo, MD, PhD, on Evaluating GD2-Directed CAR-T in Pediatric NeuroblastomaThe medical doctor and scientist at Bambino Gesù Chidren’s Hospital discussed phase 1/2 clinical trial data she presented at ASGCT’s 2024 Meeting.
Latest:
Florian Eichler, MD, on Addressing Unmet Needs in Canavan Disease With Gene TherapyThe neurologist at Massachusetts General Hospital discussed BBP-812, an investigational AAV vector-based gene therapy being evaluated for Canavan disease in a phase 1/2 trial.
Latest:
Cell Therapy May Yield Deep Remissions in Multiple MyelomaIde-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.
Latest:
Bruce Cree, MD, PhD, MAS, on the Importance of Understanding Disease Pathobiology for Novel Treatment ApproachesThe clinical research director of the UCSF Multiple Sclerosis Center discussed the difference between developing targeted therapies for well-understood diseases like SCD and less well-understood diseases like MS.
Latest:
Raising Awareness of CAR T Therapy for Mantle Cell Lymphoma: Luhua Wang, MDThe professor from The University of Texas MD Anderson Cancer Center discussed growing awareness of CAR T-cell therapy among community oncologists and patients with mantle cell lymphoma.
Latest:
Shankar Musunuri, PhD, on Continuing Research With Gene Therapy in Inherited Retinal DiseasesThe chairman, chief executive officer, and cofounder of Ocugen discussed programs including OCU400 and OCU410.
Latest:
Peter Bross, MD, on the Importance of Transparency and Communication With the FDAThe chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
Latest:
Adam Cuker, MD, on Higher Efficacy of Gene Therapy Over SOC in Hemophilia BThe associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogene elaparvovec.
Latest:
ASC Transplant Eligibility in Multiple Myeloma: Elisabet E. Manasanch, MDThe associate professor from The University of Texas MD Anderson Cancer Center discussed eligibility for autologous stem cell transplant in patients with multiple myeloma.
Latest:
Optimizing CAR T Therapies for Gastric CancerHong Ma, senior vice president, clinical development, cancer immunotherapy, CARSgen, discussed data from a phase 1 trial of CT041.
Latest:
Jacob Appelbaum, MD, PhD, on Investigating SC-DARIC33 and IL-15 for AMLThe senior research fellow at Fred Hutch Cancer Center discussed research trends at the 2023 ASGCT meeting.
Latest:
Rita Perlingeiro, PhD, on the Potential of iPS Cell-based Regenerative Medicine in Muscular DystrophyThe Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota spoke about preclinical research with an iPS cell-derived product.
